We are live on ! Find out more
FCMI

Foresite Capital Management I Portfolio holdings

AUM $21.4M
1-Year Est. Return 80.48%
This Fund
S&P 500
This Quarter Est. Return
+12.78%
1 Year Est. Return
-80.48%
3 Year Est. Return
-40.72%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$190M
AUM Growth
-$165M
Cap. Flow
-$217M
Cap. Flow %
-114.19%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$617K

Top Sells

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$218M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.55B
$177M 93.12%
1,250,000
-1,500,000
-55% -$218M
NVAX icon
2
Novavax
NVAX
$1.35B
$7.45M 3.92%
66,810
– –
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$3.19M 1.68%
293,759
+50,000
+21% +$617K
XLRN
4
DELISTED
Acceleron Pharma
XLRN
$2.44M 1.29%
19,100
– –

Similar funds

A
Atlassian San Francisco, California $21M AUM 71.86% 1-Year Est. Return
CVGI
Craft Ventures GP II San Francisco, California $24.1M AUM 83.06% 1-Year Est. Return
AEPI
AH Equity Partners IV Menlo Park, California $24.5M AUM 73.4% 1-Year Est. Return
AGDR
AdamCapital Gestao de Recursos Rio De Janeiro, Brazil $18.1M AUM 32.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
WL
WiL LLC Palo Alto, California $17.5M AUM 75.04% 1-Year Est. Return
NVPX
Norwest Venture Partners XIII Palo Alto, California $25.8M AUM 76.52% 1-Year Est. Return
SVGI
Sozo Ventures GP I Redwood City, California $16.3M AUM 66.18% 1-Year Est. Return

Foresite Capital Management I's Q4 2020 Portfolio in Review

As of Q4 2020, Foresite Capital Management I held 4 positions worth $190M, down 46% from $355M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management I withdrew a net $217M in Q4 2020, reducing 1 holding. Its largest reduction was 10x Genomics, cutting an estimated $218M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management I added an estimated $617K to Epizyme, Inc.

  • Foresite Capital Management I added most to Epizyme, Inc in Q4 2020, an estimated $617K increase.
  • Foresite Capital Management I's biggest Q4 2020 reduction was 10x Genomics, cutting an estimated $218M.
  • Foresite Capital Management I's ten largest holdings make up 100% of its $190M portfolio in Q4 2020.
  • Foresite Capital Management I opened 0 new positions and closed 0 in Q4 2020.
  • Foresite Capital Management I's portfolio value fell 46% quarter-over-quarter to $190M.

Based on Foresite Capital Management I's 13F filing for Q4 2020, filed 16 Feb 2021.